Basel, Switzerland
BioCopy is a Swiss-German biotech company with headquarters in Basel and a state-of-the-art R&D facility in Emmendingen, Germany. The company focuses on drastically accelerating the development of safe and effective next-generation cancer drugs to improve the chance of a cure significantly. BioCopy combines artificial intelligence with its automated end-to-end engineering platform to create biotherapeutics with unrivalled efficacy and safety that are transforming the R&D process in today's pharmaceutical industry. The BioCopy platform generates data sets of high quality and quantity currently unmatched in the industry that are essential to leverage the potential of AI. This synergy reduces the research and develop-ment time of next-generation biotherapeutics from approx. 3 years to 12 months. It will save valuable time in the fight against cancer and significantly reduce the cost of cancer therapeutics. In the long term, BioCopy will expand its efforts beyond cancer and develop biotherapeutics for immunological and neurological diseases. The company is managed by Dr Matthias Wiedenfels, a proven expert and industry insider in the pharmaceutical and biotechnology industry, not least through his time as CEO of STADA Arzneimittel AG. part of the prostate. ProVee is a First-Line Interventional Therapy (FIT) for BPH.
No key contacts have been added to this profile yet.
No reviews have been added to this profile yet.
This is the company profile page for BioCopy on the Pharmaceutical Services Directory. Companies listed on the directory can update their business information free of charge. If this is your company and you'd like to claim this profile, please Contact Us.
